Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance Biotherapeutics announced that the FDA has approved an Investigational New Drug Application for IOV-4001, its first genetically modified TIL therapy, aimed at treating unresectable metastatic melanoma and stage III or IV NSCLC.
This therapy utilizes TALEN® gene-editing technology licensed from Cellectis to target the PD-1 protein, potentially improving T cell response against cancer. A clinical study is set to commence in 2022, marking a significant milestone in Iovance's TIL platform development.
Iovance Biotherapeutics (NASDAQ: IOVA) announced the acceptance of two abstracts for presentation at the AACR 2022 Annual Meeting, scheduled for April 8-13, 2022, in New Orleans, Louisiana, and virtually. The first abstract focuses on the preclinical activity of genetically modified PDCD-1 knockout TIL cell therapy, presented by Arvind Natarajan. The second abstract highlights a Phase 2 multicenter trial (IOV-LUN-202) of autologous TIL therapy in metastatic non-small cell lung cancer, presented by Jason Alan Chesney. Posters will be available from April 8 in the Virtual ePoster Hall.
Iovance Biotherapeutics reported its fourth quarter and full year 2021 results, highlighting continued advancements in TIL therapy for various solid tumors, notably melanoma and non-small cell lung cancer. The FDA granted fast track designation for lifileucel combined with pembrolizumab in metastatic melanoma. However, the company experienced a net loss of $99.3 million for Q4 2021 and $342.3 million for the full year, with rising R&D and administrative expenses. Iovance ended 2021 with a cash position of $602.1 million, projected to sustain operations into 2024.
Iovance Biotherapeutics announced the approval of stock options for 138,575 shares to nineteen new non-executive employees on February 17, 2022, under its 2021 Inducement Plan. The options, priced at $16.34 per share, will vest over three years, with one-third vesting on the first anniversary of each employee's start date. Iovance focuses on T cell-based cancer immunotherapy, aiming to deliver innovative treatments for solid tumors. The company’s lead candidate, lifileucel, shows potential to be the first approved one-time cell therapy for metastatic melanoma.
Iovance Biotherapeutics (NASDAQ: IOVA) will release its Q4 and full-year financial results on February 24, 2022, with a conference call at 4:30 p.m. ET. The company is focused on developing T cell-based cancer immunotherapies, particularly its lead product candidate, lifileucel, for metastatic melanoma, potentially becoming the first approved one-time cell therapy for solid tumors. The press release emphasizes ongoing innovation in cell therapy and highlights Iovance's commitment to improving cancer treatment.
Iovance Biotherapeutics announced the grant of 117,000 inducement stock options to 13 new non-executive employees as part of its 2021 Inducement Plan. The options were priced at $14.04, the closing stock price on January 21, 2022. Each option vests over three years, with one-third vesting on the first anniversary of the employee's start date and the remainder in quarterly installments. This action aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Iovance's commitment to attract and retain talent in the field of cancer immunotherapy.
Iovance Biotherapeutics (NASDAQ: IOVA) announced the appointment of Dr. Raj K. Puri as Executive VP of Regulatory Strategy and Translational Medicine, effective Q1 2022. Dr. Puri brings over 33 years of FDA experience, notably leading the Division of Cellular and Gene Therapies. His expertise includes evaluating advanced therapies like T cell immunotherapy and cancer vaccines. Interim CEO Frederick G. Vogt expressed excitement about Dr. Puri's role in enhancing clinical and preclinical programs, contributing significantly to Iovance's mission of improving patient care through accessible T cell-based therapies.
Iovance Biotherapeutics announced successful manufacturing of tumor-infiltrating lymphocyte (TIL) therapy from cryopreserved tumor samples shipped from Australia. This innovation may address shipment challenges and enhance global access to TIL therapy. The company will present findings at the upcoming Tandem Meetings from February 2-6, 2022, in Salt Lake City, Utah. Two key abstracts will be presented, including results on ex vivo expansion of TILs and their treatment with decitabine. Iovance aims to lead in developing TIL therapies for cancer, particularly lifileucel for metastatic melanoma.
Iovance Biotherapeutics (NASDAQ: IOVA) announced that Fred Vogt, Interim CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The event will feature a live and archived webcast available on their website. Iovance is focused on developing T cell-based immunotherapies, with a lead candidate, lifileucel, showing promise for treating metastatic melanoma. The company emphasizes innovation in cell therapy aimed at improving cancer care.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) granted inducement stock options for 107,900 shares to eleven new non-executive employees on December 16, 2021. This grant is part of Iovance's 2021 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $17.80, equivalent to the closing price on the grant date. Each option vests over three years, with one-third vesting after one year and the rest quarterly thereafter, contingent on continued employment.